FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385988730> ?p ?o ?g. }

• W4385988730 endingPage "287" @default.
• W4385988730 startingPage "273" @default.
• W4385988730 abstract "The primary cause of cisplatin resistance in liver cancer is reduced intracellular drug accumulation and altered DNA repair/apoptosis signaling. Existing strategies to reverse cisplatin resistance have limited efficacy, as they target individual factors. This study proposes a drug delivery system consisting of a cisplatin core, a silica shell with a tetra-sulfide bond, and a PEG-coated surface (Core/shell-PGCN). The system is designed to consume glutathione (GSH) and reduce cisplatin excretion from cells, thereby overcoming acquired cisplatin resistance. In addition, Core/shell-PGCN incorporates PTC-209 (Core/shell-PGCN@PTC-209), a Bmi1 inhibitor that suppresses liver cancer stem cells (CSC), to mitigate DNA repair/apoptosis signaling and reverse intrinsic cisplatin resistance. In vivo and in vitro results demonstrate that Core/shell-PGCN@PTC-209 can comprehensively regulate GSH and CSC, reverse intrinsic and acquired cisplatin resistance, and enhance the efficacy of cisplatin in treating liver cancer. This inner cultivation, outer action approach may offer a new strategy for reversing cisplatin resistance in liver cancer. STATEMENT OF SIGNIFICANCE: Cisplatin resistance is widely observed in liver cancer (HCC) chemotherapy, with two mechanisms identified: acquired and intrinsic. Most strategies aimed at overcoming cisplatin resistance focus on a single perspective. This study introduces a core-shell drug delivery system (DDS) combined with HCC stem cell inhibitors, which can effectively address cisplatin resistance in HCC by targeting both acquisition and internality. Specifically, the core-shell drug delivery system can impede cisplatin efflux by neutralizing the acquired resistance factor (GSH), thus overcoming acquired resistance. Additionally, HCC stem cell inhibitors can reverse intrinsic resistance by inhibiting HCC stem cells. Therefore, this study contributes to the application of DDS in combating drug resistance in HCC and enhances its potential for clinical implementation." @default.
• W4385988730 created "2023-08-19" @default.
• W4385988730 creator A5024830909 @default.
• W4385988730 creator A5038326454 @default.
• W4385988730 creator A5046376315 @default.
• W4385988730 creator A5081239726 @default.
• W4385988730 creator A5085854173 @default.
• W4385988730 creator A5086529957 @default.
• W4385988730 creator A5092663187 @default.
• W4385988730 date "2023-10-01" @default.
• W4385988730 modified "2023-10-17" @default.
• W4385988730 title "Core-shell cisplatin/SiO2 nanocapsules combined with PTC-209 overcome chemotherapy–Acquired and intrinsic resistance in hepatocellular carcinoma" @default.
• W4385988730 cites W159782486 @default.
• W4385988730 cites W1792828569 @default.
• W4385988730 cites W1966231387 @default.
• W4385988730 cites W2010653264 @default.
• W4385988730 cites W2032084645 @default.
• W4385988730 cites W2055254495 @default.
• W4385988730 cites W2056852544 @default.
• W4385988730 cites W2063994814 @default.
• W4385988730 cites W2067117419 @default.
• W4385988730 cites W2071187736 @default.
• W4385988730 cites W2087106096 @default.
• W4385988730 cites W2094743676 @default.
• W4385988730 cites W2097365930 @default.
• W4385988730 cites W2120997349 @default.
• W4385988730 cites W2141037581 @default.
• W4385988730 cites W2150765758 @default.
• W4385988730 cites W2164277862 @default.
• W4385988730 cites W2165535625 @default.
• W4385988730 cites W2169513844 @default.
• W4385988730 cites W2172246882 @default.
• W4385988730 cites W2208298628 @default.
• W4385988730 cites W2293100631 @default.
• W4385988730 cites W2410662190 @default.
• W4385988730 cites W2478564326 @default.
• W4385988730 cites W2529674712 @default.
• W4385988730 cites W2617370963 @default.
• W4385988730 cites W2744602868 @default.
• W4385988730 cites W2763367287 @default.
• W4385988730 cites W2793318975 @default.
• W4385988730 cites W2805025035 @default.
• W4385988730 cites W2806530998 @default.
• W4385988730 cites W2809388839 @default.
• W4385988730 cites W2883657705 @default.
• W4385988730 cites W2909963991 @default.
• W4385988730 cites W2911532461 @default.
• W4385988730 cites W2912580313 @default.
• W4385988730 cites W2938932754 @default.
• W4385988730 cites W2939737815 @default.
• W4385988730 cites W2946585461 @default.
• W4385988730 cites W2966411388 @default.
• W4385988730 cites W3035992658 @default.
• W4385988730 cites W3037452658 @default.
• W4385988730 cites W3044095240 @default.
• W4385988730 cites W3090436853 @default.
• W4385988730 cites W3121912696 @default.
• W4385988730 cites W3188334818 @default.
• W4385988730 cites W3198675921 @default.
• W4385988730 cites W3216163711 @default.
• W4385988730 cites W4212773364 @default.
• W4385988730 cites W4290098745 @default.
• W4385988730 cites W4292533888 @default.
• W4385988730 cites W4294316884 @default.
• W4385988730 cites W4323852177 @default.
• W4385988730 doi "https://doi.org/10.1016/j.actbio.2023.08.021" @default.
• W4385988730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37597681" @default.
• W4385988730 hasPublicationYear "2023" @default.
• W4385988730 type Work @default.
• W4385988730 citedByCount "0" @default.
• W4385988730 crossrefType "journal-article" @default.
• W4385988730 hasAuthorship W4385988730A5024830909 @default.
• W4385988730 hasAuthorship W4385988730A5038326454 @default.
• W4385988730 hasAuthorship W4385988730A5046376315 @default.
• W4385988730 hasAuthorship W4385988730A5081239726 @default.
• W4385988730 hasAuthorship W4385988730A5085854173 @default.
• W4385988730 hasAuthorship W4385988730A5086529957 @default.
• W4385988730 hasAuthorship W4385988730A5092663187 @default.
• W4385988730 hasBestOaLocation W43859887301 @default.
• W4385988730 hasConcept C114851261 @default.
• W4385988730 hasConcept C126322002 @default.
• W4385988730 hasConcept C150903083 @default.
• W4385988730 hasConcept C185592680 @default.
• W4385988730 hasConcept C190283241 @default.
• W4385988730 hasConcept C207001950 @default.
• W4385988730 hasConcept C2776231280 @default.
• W4385988730 hasConcept C2776694085 @default.
• W4385988730 hasConcept C2778019345 @default.
• W4385988730 hasConcept C2778239845 @default.
• W4385988730 hasConcept C502942594 @default.
• W4385988730 hasConcept C55493867 @default.
• W4385988730 hasConcept C71924100 @default.
• W4385988730 hasConcept C86803240 @default.
• W4385988730 hasConcept C89423630 @default.
• W4385988730 hasConcept C98274493 @default.
• W4385988730 hasConceptScore W4385988730C114851261 @default.
• W4385988730 hasConceptScore W4385988730C126322002 @default.
• W4385988730 hasConceptScore W4385988730C150903083 @default.

• next